Sustained Delivery of GLP-1 Receptor Agonists from Injectable Biomimetic Hydrogels Improves Treatment of Diabetes.
Andrea I Dâ AquinoCaitlin L MaikawaLeslee T NguyenKatie LuIan A HallAlexander N ProssnitzEnmian ChangSam W BakerCatherine M KasseCarolyn K JonsJerry YanLars HovgaardDorte B SteensgaardHanne B AndersenLotte SimonsenEric A AppelPublished in: bioRxiv : the preprint server for biology (2023)
An injectable hydrogel depot technology prolongs delivery of GLP-1 mimics to generate a months-long-acting drug product, enhancing disease management.